Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

Patients harboring CRLF2-rearranged B-lineage acute lymphocytic leukemia (B-ALL) face a 5-year survival rate as low as 20%. While significant gains have been made to position targeted therapies for B-ALL treatment, continued efforts are needed to develop therapeutic options with improved duration of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Ze, Shi, Chunhua, Yang, Guojun, Allen, Jason K., Shi, Qing, AL-Shami, Amin, Olson, Jill Wardell, Smith, Melinda G., Chang, Qing, Kaur, Jasbir, You, Junping, Lofton, Timothy E., Gonzalez, Michelle A., Zhang, Qi, Zha, DongXing, Tasian, Sarah K., Jain, Nitin, Konopleva, Marina Y., Heffernan, Timothy, Molldrem, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539166/
https://www.ncbi.nlm.nih.gov/pubmed/37634013
http://dx.doi.org/10.1038/s41375-023-02010-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539166/
https://www.ncbi.nlm.nih.gov/pubmed/37634013
http://dx.doi.org/10.1038/s41375-023-02010-y

Ejemplares similares